Anne Claire Marrast

Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials

Dale N. Gerding, Oliver A. Cornely, Simon Grill et al. · The Lancet Infectious Diseases · 2019 · 65 citations

Medicine, Infectious Diseases, Pharmacology +5

Treatment of asymptomatic carriers with artemether-lumefantrine: an opportunity to reduce the burden of malaria?

Bernhards Ogutu, Alfred B. Tiono, Michael Makanga et al. · Malaria Journal · 2010 · 59 citations · Full text

Veterinary Medicine, Infectious Disease Control, Infectious Diseases +17

A randomized, double-blind, phase 2b study to investigate the efficacy, safety, tolerability and pharmacokinetics of a single-dose regimen of ferroquine with artefenomel in adults and children with uncomplicated Plasmodium falciparum malaria

Adoke Yeka, Rella Zoleko‐Manego, Serge Ouoba et al. · Malaria Journal · 2021 · 59 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial

Bernhards Ogutu, Adoke Yeka, Sylvia Kusemererwa et al. · The Lancet Infectious Diseases · 2023 · 40 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial

Nomathemba Chandiwana, Chelsea Kruger, Hilary Johnstone et al. · EBioMedicine · 2022 · 19 citations · Full text

Pharmacy, Infectious Diseases, Pharmacology +15